安进(AMGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AMGN 安进

休市中 04-02 16:00:00 EDT

347.94

-5.34

-1.51%

盘后347.78

-0.16-0.05%

19:50 EDT

最高354.16	最低345.87	成交量160.41万
今开352.72	昨收353.28	日振幅2.35%
总市值1,874亿	流通市值1,868亿	总股本5.38亿
成交额5.59亿	换手率0.30%	流通股本5.37亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AMGN","market":"US","secType":"STK","nameCN":"安进","latestPrice":347.94,"timestamp":1775160000000,"preClose":353.28,"halted":0,"volume":1604073,"hourTrading":{"tag":"盘后","latestPrice":347.78,"preClose":347.94,"latestTime":"19:50 EDT","volume":84883,"amount":29534431.8886,"timestamp":1775173853358,"change":-0.16,"changeRate":-0.00046,"amplitude":0.002629},"delay":0,"changeRate":-0.015115489130434713,"floatShares":536994627,"shares":538480671,"eps":14.23,"marketStatus":"休市中","change":-5.34,"latestTime":"04-02 16:00:00 EDT","open":352.72,"high":354.16,"low":345.87,"amount":559200059.1198,"amplitude":0.023466,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":14.23,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1775462400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":423288000000,"exchange":"NASDAQ","adjPreClose":353.28,"dividendRate":0.027763,"preHourTrading":{"tag":"盘前","latestPrice":351.92,"preClose":353.28,"latestTime":"09:29 EDT","volume":1065,"amount":374983.48605,"timestamp":1775136592096,"change":-1.36,"changeRate":-0.00385,"amplitude":0.023006},"postHourTrading":{"tag":"盘后","latestPrice":347.78,"preClose":347.94,"latestTime":"19:50 EDT","volume":84883,"amount":29534431.8886,"timestamp":1775173853358,"change":-0.16,"changeRate":-0.00046,"amplitude":0.002629},"volumeRatio":0.5997740734823798,"impliedVol":0.3512,"impliedVolPercentile":0.9004},"requestUrl":"/m/hq/s/AMGN","defaultTab":"news","newsList":[{"id":"2624524927","title":"再鼎医药午前涨近5% 与安进公司达成一项全球临床研究合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2624524927","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624524927?lang=zh_cn&edition=full","pubTime":"2026-04-02 11:37","pubTimestamp":1775101020,"startTime":"0","endTime":"0","summary":"　　再鼎医药午前涨超4%，截至发稿，股价上涨4.82%，现报15.88港元，成交额2.88亿港元。　　作为该合作协议的一部分，安进将申办一项全球1b期研究，评估zoci联合IMDELLTRA在ES-SCLC患者中的安全性和有效性。再鼎医药将保留zoci的完整所有权，并将向安进提供临床研究用药。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-04-02/doc-inhtaraa1102717.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["AMGN","BK4531","IE00BFTCPJ56.SGD","LU1983299246.USD","BK4534","BK1574","LU2468319806.SGD","LU1571399168.USD","BK4566","LU1057294990.SGD","LU1061106388.HKD","LU0320765992.SGD","BK4139","LU0868494617.USD","BK1588","BK4581","IE00BJJMRZ35.SGD","BK4588","IE00B4R5TH58.HKD","LU2242646821.SGD","LU2488822045.USD","BK4585","BK4548","LU2089984988.USD","ZLAB","09688","BK4526","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU2242652126.USD","LU0289739699.SGD","LU1023059063.AUD","LU0889565916.HKD","SG9999001440.SGD","IE0002141913.USD","BK4599","LU2112291526.USD","IE0009355771.USD","BK1161","LU0122379950.USD","BK4533","LU0058720904.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624556767","title":"美国FDA就与安进罕见病药物有关的肝损伤病例发出警告","url":"https://stock-news.laohu8.com/highlight/detail?id=2624556767","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624556767?lang=zh_cn&edition=full","pubTime":"2026-04-01 14:48","pubTimestamp":1775026119,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["AMGN","LU0058720904.USD","BK4581","LU0889565916.HKD","LABU","LU0320765992.SGD","LU1057294990.SGD","IE0009355771.USD","IE00BJT1NW94.SGD","BK4588","BK4533","BK4139","IE0002141913.USD","BK4566","LU1571399168.USD","LU2112291526.USD","LU1023059063.AUD","LU2468319806.SGD","LU1061106388.HKD","LU0122379950.USD","LU2089984988.USD","BK4599","IE00BJJMRZ35.SGD","LU2242652126.USD","LU0868494617.USD","IE00B4R5TH58.HKD","LU2242646821.SGD","LU0109394709.USD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","LU1983299246.USD","BK4534","BK4585","LU0289739699.SGD","SG9999001440.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179256799","title":"FDA警示：Tavneos出现胆管消失综合征及致死性药物性肝损伤病例 构成新安全隐患","url":"https://stock-news.laohu8.com/highlight/detail?id=1179256799","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179256799?lang=zh_cn&edition=full","pubTime":"2026-03-31 21:10","pubTimestamp":1774962657,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）近期发布安全警示，抗炎药物Tavneos（avacopan）在临床使用中出现了胆管消失综合征及致死性药物性肝损伤的病例报告，这些严重不良反应构成了该药物新的安全性隐忧。\n胆管消失综合征是一种罕见的严重肝损伤，其特征为肝内胆管进行性破坏消失。而此次报告的药物性肝损伤病例已出现致命后果。监管机构指出，医疗专业人员需对接受Tavneos治疗的患者保持高度警惕，密切监测其肝功能指标。\n此次安全信号的浮现，为Tavneos的风险效益评估增添了新的考量维度。临床医生在处方时应充分权衡其治疗潜力与潜在的严重肝毒性风险。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN","LU0058720904.USD","BK4581","LU0889565916.HKD","LU0320765992.SGD","LU1057294990.SGD","IE0009355771.USD","IE00BJT1NW94.SGD","BK4588","BK4533","BK4139","IE0002141913.USD","BK4566","LU1571399168.USD","LU2112291526.USD","LU1023059063.AUD","LU2468319806.SGD","LU1061106388.HKD","LU0122379950.USD","LU2089984988.USD","BK4599","IE00BJJMRZ35.SGD","LU2242652126.USD","LU0868494617.USD","IE00B4R5TH58.HKD","LU2242646821.SGD","LU0109394709.USD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","LU1983299246.USD","BK4534","BK4585","LU0289739699.SGD","SG9999001440.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192752433","title":"安进公布Vesalius-Cv三期临床试验结果：Repatha显著降低心肌梗死、冠心病死亡及缺血性卒中风险","url":"https://stock-news.laohu8.com/highlight/detail?id=1192752433","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192752433?lang=zh_cn&edition=full","pubTime":"2026-03-29 04:46","pubTimestamp":1774730776,"startTime":"0","endTime":"0","summary":"安进公司宣布，其开展的Vesalius-Cv三期临床试验取得积极成果。数据显示，使用Repatha（瑞百安）可显著降低患者发生心肌梗死、冠心病相关死亡以及缺血性卒中的综合风险。\n该临床试验结果进一步证实了Repatha在心血管疾病二级预防中的治疗价值，为存在心血管事件高风险的患者提供了重要的临床证据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","BK4534","BK4566","LU0868494617.USD","LU1023059063.AUD","LU2468319806.SGD","IE00B2B36J28.USD","BK4585","BK4139","BK4581","LU2089984988.USD","LU1061106388.HKD","LU2242646821.SGD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU1057294990.SGD","BK4599","LU0320765992.SGD","LU1983299246.USD","LU0058720904.USD","IE00BJT1NW94.SGD","BK4533","AMGN","LU0289739699.SGD","SG9999001440.SGD","IE0002141913.USD","LU0109394709.USD","IE0009355771.USD","BK4588","LU0889565916.HKD","LU1571399168.USD","IE00BFTCPJ56.SGD","LU2242652126.USD","LU2112291526.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146126461","title":"EMA人用药品委员会：Joenja（Leniolisib）获特殊情况下上市许可积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=1146126461","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146126461?lang=zh_cn&edition=full","pubTime":"2026-03-27 19:45","pubTimestamp":1774611913,"startTime":"0","endTime":"0","summary":"欧洲药品管理局（EMA）人用药品委员会（CHMP）已对Joenja（Leniolisib）发出积极意见，建议其在特殊情况下授予上市许可。这一关键进展为特定患者群体的治疗带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","SG9999001440.SGD","LU2468319806.SGD","LU0289739699.SGD","LU1983299246.USD","LU2112291526.USD","IE00B4R5TH58.HKD","LU2242646821.SGD","LU2089984988.USD","IE00B2B36J28.USD","BK4566","IE0009355771.USD","LU1057294990.SGD","IE00BJT1NW94.SGD","LU1061106388.HKD","LU0109394709.USD","IE00BFTCPJ56.SGD","LU1571399168.USD","LU0868494617.USD","BK4139","IE00BJJMRZ35.SGD","BK4534","LU0320765992.SGD","IE0002141913.USD","BK4533","LU0889565916.HKD","BK4581","LU2242652126.USD","LU1023059063.AUD","LU0058720904.USD","BK4599","LU0122379950.USD","AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109151850","title":"欧洲药品管理局人用医药产品委员会建议批准Imdylltra（Tarlatamab）用于复发广泛期小细胞肺癌治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1109151850","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109151850?lang=zh_cn&edition=full","pubTime":"2026-03-27 19:43","pubTimestamp":1774611797,"startTime":"0","endTime":"0","summary":"欧洲药品管理局人用医药产品委员会（CHMP）近日发布积极意见，建议授予安进公司开发的靶向疗法Imdylltra（Tarlatamab）上市许可。该药物拟用于治疗既往接受过系统性治疗的复发广泛期小细胞肺癌患者。\n此次推荐基于关键临床研究数据，显示Tarlatamab作为双特异性T细胞衔接抗体，能显著激活患者自身免疫系统攻击肿瘤细胞。若最终获欧盟委员会批准，这将成为首款针对该适应症的靶向免疫疗法，为预后极差的晚期肺癌群体提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","LU0889565916.HKD","LU0058720904.USD","LU1057294990.SGD","BK4585","IE0002141913.USD","BK4139","LU0109394709.USD","LU1983299246.USD","IE0009355771.USD","LU2112291526.USD","LU2089984988.USD","LU0122379950.USD","BK4566","LU2468319806.SGD","BK4588","LU2242652126.USD","LU0320765992.SGD","LU1571399168.USD","LU0289739699.SGD","LU1061106388.HKD","BK4534","BK4599","BK4581","LU0868494617.USD","IE00BFTCPJ56.SGD","LU1023059063.AUD","AMGN","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","SG9999001440.SGD","LU2242646821.SGD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149822474","title":"协和麒麟：数周内安全审查揭示恶性肿瘤新风险，或与病毒及免疫因素相关","url":"https://stock-news.laohu8.com/highlight/detail?id=1149822474","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149822474?lang=zh_cn&edition=full","pubTime":"2026-03-03 21:05","pubTimestamp":1772543110,"startTime":"0","endTime":"0","summary":"协和麒麟公司近期完成的安全评估显示，在过去数周的分析中发现新型恶性肿瘤风险信号，这些潜在病例可能与病毒感染或免疫系统异常存在关联。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","BK4534","BK4566","LU0868494617.USD","LU1023059063.AUD","LU2468319806.SGD","IE00B2B36J28.USD","BK4585","BK4139","BK4581","LU2089984988.USD","LU1061106388.HKD","LU2242646821.SGD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU1057294990.SGD","BK4599","LU0320765992.SGD","LU1983299246.USD","LU0058720904.USD","IE00BJT1NW94.SGD","BK4533","AMGN","LU0289739699.SGD","SG9999001440.SGD","IE0002141913.USD","LU0109394709.USD","IE0009355771.USD","BK4588","LU0889565916.HKD","LU1571399168.USD","IE00BFTCPJ56.SGD","LU2242652126.USD","LU2112291526.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610684644","title":"Argus上调安进目标价至400美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610684644","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610684644?lang=zh_cn&edition=full","pubTime":"2026-02-09 15:22","pubTimestamp":1770621743,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1023059063.AUD","LU2089984988.USD","LU2242646821.SGD","LU0122379950.USD","IE00BJT1NW94.SGD","LU1571399168.USD","LU1057294990.SGD","BK4585","BK4533","LU1061106388.HKD","IE00BFTCPJ56.SGD","BK4599","LU0889565916.HKD","BK4534","BK4566","LU0868494617.USD","LU0058720904.USD","SG9999001440.SGD","LU0320765992.SGD","BK4139","BK4581","BK4588","LU2112291526.USD","AMGN","LU2468319806.SGD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU1983299246.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU2242652126.USD","LU0109394709.USD","LU0289739699.SGD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609324007","title":"花旗上调安进目标价至345美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609324007","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609324007?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:27","pubTimestamp":1770280021,"startTime":"0","endTime":"0","summary":"花旗将安进的目标价从315美元上调至345美元，维持“中性”评级。(格隆汇)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260205/32000802.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129271059","title":"安进核心业务强劲增长，抵消减肥药上市延迟影响——市场快评","url":"https://stock-news.laohu8.com/highlight/detail?id=1129271059","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129271059?lang=zh_cn&edition=full","pubTime":"2026-02-05 03:58","pubTimestamp":1770235106,"startTime":"0","endTime":"0","summary":"尽管安进公司的新型减肥药物尚需进一步测试，但其核心产品正持续推动业绩增长。威廉·布莱尔分析师指出，虽然投资者目光聚焦于减肥疗法MariTide，但该药关键的第三阶段试验结果预计要到2027年才能揭晓。在此期间，降胆固醇药物瑞百安与哮喘治疗药Tezspire等核心产品正为短期增长提供动力。\n值得注意的是，安进发布的2026年初步营收指引超出市场预期，彰显出现有产品组合的强劲实力。尽管肥胖治疗领域竞争激烈，威廉·布莱尔仍维持\"跑赢大盘\"评级，认为该股未来仍存重要临床催化剂。当前安进股价涨幅达8.5%。\n（本文根据市场公开信息整理，不构成投资建议）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","LU0320765992.SGD","LU0868494617.USD","BK4585","LU0122379950.USD","IE00BFTCPJ56.SGD","IE0002141913.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","BK4588","BK4139","LU0109394709.USD","BK4566","LU0058720904.USD","LU0289739699.SGD","LU2089984988.USD","LU2242652126.USD","IE00BJT1NW94.SGD","BK4534","LU1571399168.USD","LU2468319806.SGD","LU1057294990.SGD","LU1983299246.USD","LU0889565916.HKD","LU1061106388.HKD","LU2242646821.SGD","LU2112291526.USD","BK4599","BK4581","LU1023059063.AUD","BK4533","SG9999001440.SGD","AMGN","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608239559","title":"美股异动丨安进涨超5%创新高，Q4业绩及今年指引均超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2608239559","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608239559?lang=zh_cn&edition=full","pubTime":"2026-02-04 23:30","pubTimestamp":1770219008,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["RWM","SRTY","IE00B2B36J28.USD","LU0320765992.SGD","TNA","LU0868494617.USD","BK4585","LU0122379950.USD","IE00BFTCPJ56.SGD","IE0002141913.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","BK4588","BK4139","LU0109394709.USD","BK4566","LU0058720904.USD","LU0289739699.SGD","LU2089984988.USD","LU2242652126.USD","BK4534","BK4535","IE00BJT1NW94.SGD","LU1571399168.USD","MNQmain","LU2468319806.SGD","LU1057294990.SGD","IWO","LU1983299246.USD","LU0889565916.HKD","LU1061106388.HKD","LU2242646821.SGD","TWM","LU2112291526.USD","BK4599","IWN","TZA","04332","UWM","BK4581","LU1023059063.AUD","BK4533","SG9999001440.SGD","BK4550","AMGN","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165129857","title":"异动解读 | 安进盘中大涨5.30%，2026年盈利预测乐观及业绩超预期提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1165129857","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165129857?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:52","pubTimestamp":1770216769,"startTime":"0","endTime":"0","summary":"安进今日盘中大涨5.30%，引起了市场的广泛关注。消息面上，安进公司发布了乐观的2026年盈利预测，其预计年度调整后每股收益介于21.60美元至23美元之间，高于分析师平均预期的22.09美元。在此利好消息推动下，多家券商纷纷上调了安进的目标价，包括Leerink Partners将目标价从305美元上调至355美元，TD Cowen将目标价从389美元上调至420美元。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608633846","title":"安进Q4业绩超预期，继续推进新一代减肥药临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2608633846","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608633846?lang=zh_cn&edition=full","pubTime":"2026-02-04 10:18","pubTimestamp":1770171504,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE0002141913.USD","IE00B4R5TH58.HKD","BK4139","AMGN","LU0122379950.USD","BK4585","LU0058720904.USD","BK4599","LU0868494617.USD","SG9999001440.SGD","BK4581","LU2112291526.USD","LU1983299246.USD","IE00BJT1NW94.SGD","LU1057294990.SGD","LU1571399168.USD","LU2468319806.SGD","LU0109394709.USD","BK4533","LU1023059063.AUD","LU2242652126.USD","IE00BFTCPJ56.SGD","LU1061106388.HKD","IE00BJJMRZ35.SGD","BK4534","IE00B2B36J28.USD","LU0289739699.SGD","LU2242646821.SGD","BK4566","IE0009355771.USD","LU0889565916.HKD","BK4588","LU0320765992.SGD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608789416","title":"数十亿打水漂，安进退货自免 FIC 单抗","url":"https://stock-news.laohu8.com/highlight/detail?id=2608789416","media":"药研界面","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608789416?lang=zh_cn&edition=full","pubTime":"2026-02-02 17:10","pubTimestamp":1770023451,"startTime":"0","endTime":"0","summary":"近日，在支付了 4 亿美元首付款后，安进终止了与协和麒麟就Rocatinlimab 达成的合作。根据 Insight 数据库，Rocatinlimab 共启动了9 项 III 期临床，其中 8 项的适应症都为特应性皮炎。2025 年11 月，《The Lancet》杂志发表了该产品用于中重度特应性皮炎的两项III 期ROCKET-IGNITE 和 ROCKET-HORIZON 研究结果。这两项研究共纳入近 1500 名受试者。安全性方面，Rocatinlimab 组与安慰剂组治疗期间不良事件发生率总体相近，前者最常见的不良事件包括发热、寒战和口腔溃疡。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202175112a6c9d457&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202175112a6c9d457&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4533","LU1061106388.HKD","IE0002141913.USD","BK4581","BK4599","IE00BFTCPJ56.SGD","LU0889565916.HKD","LU0109394709.USD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","BK4534","LU0289739699.SGD","LU2468319806.SGD","LU0868494617.USD","LU2089984988.USD","LU0122379950.USD","BK4585","LU0320765992.SGD","LU1983299246.USD","LU0058720904.USD","AMGN","LU2242646821.SGD","IE0009355771.USD","BK4588","IE00B2B36J28.USD","BK4139","LU2242652126.USD","LU1023059063.AUD","LU1057294990.SGD","LU2112291526.USD","LU1571399168.USD","BK4566","SG9999001440.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607090010","title":"奥本海默上调安进目标价至400美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607090010","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607090010?lang=zh_cn&edition=full","pubTime":"2026-01-30 16:55","pubTimestamp":1769763325,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00B2B36J28.USD","LU0320765992.SGD","LU0868494617.USD","BK4585","LU0122379950.USD","IE00BFTCPJ56.SGD","IE0002141913.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","BK4588","BK4139","LU0109394709.USD","BK4566","LU0058720904.USD","LU0289739699.SGD","LU2089984988.USD","LU2242652126.USD","IE00BJT1NW94.SGD","BK4534","LU1571399168.USD","LU2468319806.SGD","LU1057294990.SGD","LU1983299246.USD","LU0889565916.HKD","LU1061106388.HKD","LU2242646821.SGD","LU2112291526.USD","BK4599","BK4581","LU1023059063.AUD","BK4533","SG9999001440.SGD","AMGN","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606728962","title":"瑞银上调安进目标价至390美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606728962","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606728962?lang=zh_cn&edition=full","pubTime":"2026-01-27 12:27","pubTimestamp":1769488022,"startTime":"0","endTime":"0","summary":"瑞银将安进的目标价从380美元上调至390美元，维持“买入”评级。(格隆汇)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260127/31975225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172625763","title":"减肥药进入“长期维持+低频注射”时代，安进“月服”优势引领千亿美元市场","url":"https://stock-news.laohu8.com/highlight/detail?id=1172625763","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172625763?lang=zh_cn&edition=full","pubTime":"2026-01-14 15:12","pubTimestamp":1768374763,"startTime":"0","endTime":"0","summary":"高盛认为在“下一代减肥药物” MariTide相关的重大催化之下，安进有望踏上价值重估轨迹，其股价上行空间相比于同行可能更加广阔。全球肥胖率持续上升，肥胖被认为是重大慢性疾病风险因素，导致对有效减重治疗的巨大需求持续扩大。随着价格下降和医保覆盖扩大，患者用药意愿和人数预计大幅提升，这将推动市场规模增长。","market":"us","thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/content/detail/1392679.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"减肥药进入“长期维持+低频注射”时代，安进“月服”优势引领千亿美元市场","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4585","BK4588","LU1023059063.AUD","BK4599","IE00B2B36J28.USD","BK4139","LU0289739699.SGD","LU0868494617.USD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU1061106388.HKD","LU1571399168.USD","LU1983299246.USD","BK4533","LU0122379950.USD","LU0320765992.SGD","BK4581","LU0889565916.HKD","BK4534","BK4566","IE0009355771.USD","LU1057294990.SGD","LU2112291526.USD","LU2089984988.USD","LU2242646821.SGD","AMGN","LU0058720904.USD","LU0109394709.USD","LU2242652126.USD","SG9999001440.SGD","LU2468319806.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603674356","title":"减肥药进入“长期维持+低频注射”时代 安进(AMGN.US)“月服”优势引领千亿美元市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2603674356","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603674356?lang=zh_cn&edition=full","pubTime":"2026-01-14 14:57","pubTimestamp":1768373853,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，美国大型制药/生物科技巨头安进公司当地时间周一透露，其试验性的减肥药——即有着“下一代减肥药”称号的GLP-1相关联药物MariTide的一项最新临床试验结果显示，当肥胖症患者们每月仅仅注射一次时，他们能够在两年内稳定保持体重下降趋势。随着价格下降和医保覆盖扩大，患者用药意愿和人数预计大幅提升，这将推动市场规模增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392679.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"减肥药进入“长期维持+低频注射”时代 安进(AMGN.US)“月服”优势引领千亿美元市场","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2242652126.USD","BK4599","LU0868494617.USD","BK4566","LU1061106388.HKD","LU2089984988.USD","IE00BJT1NW94.SGD","LU1057294990.SGD","LU1571399168.USD","SG9999001440.SGD","BK4581","BK4533","IE00B2B36J28.USD","IE0002141913.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU2242646821.SGD","BK4534","LU1023059063.AUD","BK4585","LU2112291526.USD","LU2468319806.SGD","IE00BFTCPJ56.SGD","LU0289739699.SGD","AMGN","BK4588","LU0109394709.USD","BK4139","LU1983299246.USD","LU0122379950.USD","LU0889565916.HKD","LU0320765992.SGD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148445500","title":"安进：Maritide扩展研究52周数据显示，绝大多数受试者采用较低月剂量或季度剂量后维持二期试验第一阶段减重效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1148445500","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148445500?lang=zh_cn&edition=full","pubTime":"2026-01-13 07:53","pubTimestamp":1768262001,"startTime":"0","endTime":"0","summary":"安进公司最新公布的Maritide扩展研究结果显示，在为期52周的延长试验期间，绝大多数接受较低月度剂量或季度剂量给药的参与者，成功维持了在二期临床试验第一阶段所达到的体重减轻效果。这项扩展研究旨在评估不同给药方案对体重维持的长期影响，初步数据表明药物在延长用药周期后仍能保持疗效稳定性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2242652126.USD","LU0289739699.SGD","IE0002141913.USD","BK4566","LU2468319806.SGD","BK4588","LU1023059063.AUD","BK4139","LU0320765992.SGD","IE0009355771.USD","LU1983299246.USD","LU2112291526.USD","SG9999001440.SGD","IE00BJT1NW94.SGD","LU0122379950.USD","BK4534","BK4599","IE00BFTCPJ56.SGD","LU0889565916.HKD","IE00B4R5TH58.HKD","LU1571399168.USD","LU1061106388.HKD","IE00B2B36J28.USD","LU2242646821.SGD","IE00BJJMRZ35.SGD","AMGN","BK4581","LU2089984988.USD","LU1057294990.SGD","LU0058720904.USD","LU0109394709.USD","BK4533","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117228263","title":"安进：Maritide治疗第二年耐受性良好，季度剂量方案下恶心呕吐发生率极低且无新增安全信号","url":"https://stock-news.laohu8.com/highlight/detail?id=1117228263","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117228263?lang=zh_cn&edition=full","pubTime":"2026-01-13 07:53","pubTimestamp":1768261997,"startTime":"0","endTime":"0","summary":"安进公司最新研究数据显示，其药物Maritide在第二年治疗期间展现出优异的耐受性特征。值得注意的是，即便是采用季度给药方案，患者的不良反应发生率仍维持在极低水平。\n临床观察表明，治疗组恶心和呕吐等胃肠道不良事件的发生率显著偏低。更关键的是，在整个第二年研究周期内，未监测到任何新的安全性信号，这进一步印证了该疗法的可靠性和安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0889565916.HKD","LU1023059063.AUD","LU0058720904.USD","LU0109394709.USD","LU2112291526.USD","IE0002141913.USD","IE00BJT1NW94.SGD","SG9999001440.SGD","BK4581","IE0009355771.USD","LU2242652126.USD","BK4585","BK4139","LU0122379950.USD","LU1057294990.SGD","LU0320765992.SGD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU1061106388.HKD","LU1571399168.USD","IE00B4R5TH58.HKD","LU1983299246.USD","IE00B2B36J28.USD","BK4533","AMGN","LU2089984988.USD","BK4566","LU0289739699.SGD","LU2242646821.SGD","BK4599","LU0868494617.USD","BK4534","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.amgen.com","stockEarnings":[{"period":"1week","weight":-0.0148},{"period":"1month","weight":-0.0771},{"period":"3month","weight":0.062},{"period":"6month","weight":0.168},{"period":"1year","weight":0.1382},{"period":"ytd","weight":0.063}],"compareEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":-0.036},{"period":"3month","weight":-0.04},{"period":"6month","weight":-0.02},{"period":"1year","weight":0.1617},{"period":"ytd","weight":-0.0383}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"安进公司于1980年在加利福尼亚成立，并于1987年成为特拉华州的一家公司。该公司发现、开发、制造和交付创新药物，以对抗世界上一些最棘手的疾病。该公司专注于高度未满足的医疗需求领域，并利用其专业知识努力寻求能够显著改善人们生活的解决方案，同时还能减轻疾病带来的社会和经济负担。该公司在40多年前帮助启动了生物技术产业，并已成长为世界领先的独立生物技术公司之一。","yearOnYearQuotes":[{"month":1,"riseRate":0.651163,"avgChangeRate":0.034336},{"month":2,"riseRate":0.488372,"avgChangeRate":0.00202},{"month":3,"riseRate":0.511628,"avgChangeRate":0.016602},{"month":4,"riseRate":0.44186,"avgChangeRate":-0.003044},{"month":5,"riseRate":0.52381,"avgChangeRate":0.024179},{"month":6,"riseRate":0.5,"avgChangeRate":0.003875},{"month":7,"riseRate":0.767442,"avgChangeRate":0.052562},{"month":8,"riseRate":0.604651,"avgChangeRate":0.004451},{"month":9,"riseRate":0.511628,"avgChangeRate":0.002296},{"month":10,"riseRate":0.534884,"avgChangeRate":0.021538},{"month":11,"riseRate":0.627907,"avgChangeRate":0.022348},{"month":12,"riseRate":0.627907,"avgChangeRate":0.045446}],"exchange":"NASDAQ","name":"安进","nameEN":"Amgen"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"安进(AMGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供安进(AMGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"安进,AMGN,安进股票,安进股票老虎,安进股票老虎国际,安进行情,安进股票行情,安进股价,安进股市,安进股票价格,安进股票交易,安进股票购买,安进股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"安进(AMGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供安进(AMGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}